Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IM19-CD28 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Immunochina Pharmaceuticals
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IM19-CD28 CAR-T cells are an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the CD19 antigen, a protein expressed on the surface of B-cells and associated with various B-cell malignancies. This specific construct utilizes a CD28 costimulatory signaling domain, which is typically associated with rapid T-cell activation and potent effector function. Developed by Beijing Boren Hospital, IM19-CD28 is being investigated in Phase 1 clinical trials in China for the treatment of patients with relapsed or refractory CD19-positive aggressive non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL) and grade 3 follicular lymphoma. The therapy involves genetically modifying a patient's own T-cells to express the CAR, enabling them to recognize and eliminate CD19-positive tumor cells.
- Other names
- IM19 CAR-T cellsIM-19 CAR-T cellsIM 19 CAR-T cells
02
Targets
Beyond the preview
Go deeper on IM19-CD28 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IM19-CD28 CAR-T cells.